Acorda Therapeutics, Inc. (ACOR) Misses Q3 EPS Views; Reaffirms Outlook
Get Alerts ACOR Hot Sheet
Price: $13.50 --0%
Revenue Growth %: +63.1%
Financial Fact:
Net loss per share-diluted (earnings per share): -0.28
Today's EPS Names:
DSGN, ATRA, CRVS, More
Revenue Growth %: +63.1%
Financial Fact:
Net loss per share-diluted (earnings per share): -0.28
Today's EPS Names:
DSGN, ATRA, CRVS, More
Join SI Premium – FREE
Acorda Therapeutics, Inc. (NASDAQ: ACOR) reported Q3 EPS of $0.40, $0.33 worse than the analyst estimate of $0.73. Revenue for the quarter came in at $93.03 million versus the consensus estimate of $90.78 million.
Acorda reiterates its 2011 net sales guidance.
Acorda reiterates its 2011 net sales guidance.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Bit Digital (BTBT) Reports FY EPS of $0.12
- Embraer (ERJ) Tops Q4 EPS by 43c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!